Kiluma Biosciences Advances Pancreatic Cancer Early Detection with OncoIntercept™, Powered by the Intercept IQ™ Platform
Kiluma Biosciences announces continued advancement of its proprietary OncoIntercept™ program, leveraging the Intercept IQ™ platform to develop a next-generation blood-based diagnostic designed to identify pancreatic cancer at its earliest and most treatable stages.
Summary
Kiluma Biosciences is advancing a precision diagnostics platform focused on transforming pancreatic cancer detection. Powered by the proprietary Intercept IQ™ platform, OncoIntercept™ combines advanced biomarker discovery, liquid biopsy technologies, and AI-driven analytics to identify disease earlier than traditional approaches. The program represents an important step toward improving patient outcomes through earlier diagnosis and expanding the future potential of multi-cancer detection.